Revenue: As of FY2026 Q1, the actual value is USD 44.81 M, beating the estimate of USD 42 M.

EPS: As of FY2026 Q1, the actual value is USD -0.07, beating the estimate of USD -0.17.

EBIT: As of FY2026 Q1, the actual value is USD -4.099 M.

Puma Biotechnology, Inc. operates in a single reporting segment focused on the development and commercialization of innovative products to enhance cancer care .

Segment Revenue

• Total Revenue: Decreased from $46.0 million in Q1 2025 to $44.8 million in Q1 2026, representing a $1.2 million decrease .
• Product Revenue, Net: Decreased to $42.0 million in Q1 2026 from $43.1 million in Q1 2025, primarily due to higher deductions for variable consideration, partially offset by an increased selling price .
• Royalty Revenue: Remained consistent at $2.9 million for both Q1 2026 and Q1 2025 .

Operational Metrics

• Net (Loss) Income: Puma Biotechnology, Inc. reported a net loss of -$3.8 million in Q1 2026, a decline from a net income of $3.0 million in Q1 2025 .
• Cost of Sales: Was $10.4 million in Q1 2026, consistent with $10.6 million in Q1 2025 .
• Selling, General and Administrative (SG&A) Expenses: Increased by $0.8 million (4.7%) to $18.4 million in Q1 2026 from $17.6 million in Q1 2025 . Payroll and related costs increased by $0.9 million (10.6%) to $9.1 million in Q1 2026 . Professional fees and expenses increased by $0.4 million (9.4%) to $5.0 million in Q1 2026 . Provision for credit loss decreased by -$0.2 million (-100.0%) to $0 million in Q1 2026 .
• Research and Development (R&D) Expenses: Increased by $5.9 million (42.8%) to $19.8 million in Q1 2026 from $13.9 million in Q1 2025 . Clinical trial expense increased by $5.2 million (143.1%) to $8.8 million in Q1 2026, driven by increased alisertib study activity . Internal R&D expense increased by $0.7 million (8.4%) to $9.3 million in Q1 2026, primarily due to increased employee compensation .
• Interest Expense: Decreased to -$0.7 million in Q1 2026 from -$2.2 million in Q1 2025 .
• Other Income: Decreased to $0.1 million in Q1 2026 from $0.4 million in Q1 2025 .

Cash Flow

• Net Cash Provided by Operating Activities: Increased to $15.4 million in Q1 2026 from $3.6 million in Q1 2025 . This increase was primarily due to a $27.3 million decrease in accounts receivable and a $3.1 million increase in accounts payable, partially offset by an -$11.7 million decrease in accrued expenses and other, and a $3.2 million increase in inventory .
• Net Cash Provided by Investing Activities: Increased to $2.5 million in Q1 2026 from $1.5 million in Q1 2025, mainly due to the maturity of $27.3 million in available-for-sale securities, partially offset by $24.9 million in new purchases .
• Net Cash Used in Financing Activities: Remained consistent at -$11.3 million for both Q1 2026 and Q1 2025, including $11.1 million for principal payments and $0.2 million for exit fees on debt .
• Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash: Resulted in an increase of $6.6 million in Q1 2026, compared to a decrease of -$6.2 million in Q1 2025 .

Unique Metrics

• Cash and Cash Equivalents: $36.2 million as of March 31, 2026, an increase from $29.6 million as of December 31, 2025 .
• Marketable Securities: $65.4 million as of March 31, 2026, a decrease from $67.9 million as of December 31, 2025 .
• Working Capital: $82.5 million as of March 31, 2026, an increase from $81.4 million as of December 31, 2025 .
• Current Portion of Long-Term Debt: $11.3 million as of March 31, 2026, a decrease from $22.5 million as of December 31, 2025 .
• Stockholders’ Equity: $128.4 million as of March 31, 2026, a decrease from $130.3 million as of December 31, 2025 .
• Intangible Assets, Net: $39.0 million as of March 31, 2026, with an estimated remaining useful life of 4.0 years and future amortization expense of approximately $7.3 million for the remainder of 2026, $9.7 million for each year from 2027 through 2029, and $2.4 million for 2030 .
• Total Potential Milestone Payments (Sub-license Agreements): Approximately $579.8 million as of March 31, 2026 .
• Unrecognized Employee Compensation Cost: Approximately $1.7 million for non-vested stock options and $8.8 million for non-vested RSUs as of March 31, 2026 .
• 401(k) Employer-Matching Contributions: $0.6 million in Q1 2026, compared to $0.5 million in Q1 2025 .

Future Outlook and Strategy

Puma Biotechnology, Inc. anticipates significant expenses for the development of alisertib in 2026 . The company expects its existing cash, cash equivalents, and marketable securities, combined with projected product sales and sub-license payments, to meet operating cash needs for at least one year after the report’s filing . However, future funding could be affected by market conditions, the commercialization success of NERLYNX, alisertib development, regulatory decisions, or clinical trial results .